Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a publicly traded Healthcare sector company. As of May 21, 2026, CTNM trades at $13.40 with a market cap of $480.79M and a P/E ratio of -6.13. CTNM moved +5.72% today. Year to date, CTNM is +33.90%; over the trailing twelve months it is +249.61%. Its 52-week range spans $3.35 to $20.24. Analyst consensus is strong buy with an average price target of $21.00. Rallies surfaces CTNM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes CTNM SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $13.40 |
| Market Cap | $480.79M |
| P/E Ratio | -6.13 |
| EPS | $-2.17 |
| Dividend Yield | 0.00% |
| 52-Week High | $20.24 |
| 52-Week Low | $3.35 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-59.98M |
| Gross Margin | 0.00% |
6 analysts cover CTNM: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $21.00.